Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: SLC9A1

Gene summary for SLC9A1

Gene summary.

Gene information	Species	Human
	Gene symbol	SLC9A1
	Gene ID	6548
	Gene name	solute carrier family 9 member A1
	Gene Alias	APNH
	Cytomap	1p36.11
	Gene Type	protein-coding
	GO ID	GO:0001508
	UniProtAcc	B2RAH2

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
6548	SLC9A1	HTA11_2487_2000001011	Human	Colorectum	SER	7.88e-13	6.35e-01	-0.1808
6548	SLC9A1	HTA11_1938_2000001011	Human	Colorectum	AD	2.72e-07	3.64e-01	-0.0811
6548	SLC9A1	HTA11_347_2000001011	Human	Colorectum	AD	2.06e-18	6.47e-01	-0.1954
6548	SLC9A1	HTA11_411_2000001011	Human	Colorectum	SER	9.31e-03	8.29e-01	-0.2602
6548	SLC9A1	HTA11_2112_2000001011	Human	Colorectum	SER	1.23e-02	7.25e-01	-0.2196
6548	SLC9A1	HTA11_3361_2000001011	Human	Colorectum	AD	4.80e-06	5.56e-01	-0.1207
6548	SLC9A1	HTA11_83_2000001011	Human	Colorectum	SER	6.12e-05	5.17e-01	-0.1526
6548	SLC9A1	HTA11_696_2000001011	Human	Colorectum	AD	3.44e-14	7.66e-01	-0.1464
6548	SLC9A1	HTA11_866_2000001011	Human	Colorectum	AD	9.65e-03	2.88e-01	-0.1001
6548	SLC9A1	HTA11_1391_2000001011	Human	Colorectum	AD	7.84e-07	5.16e-01	-0.059
6548	SLC9A1	HTA11_5212_2000001011	Human	Colorectum	AD	1.93e-04	6.05e-01	-0.2061
6548	SLC9A1	A015-C-203	Human	Colorectum	FAP	4.96e-03	-1.14e-01	-0.1294
6548	SLC9A1	A002-C-205	Human	Colorectum	FAP	1.88e-03	-2.02e-01	-0.1236
6548	SLC9A1	A015-C-104	Human	Colorectum	FAP	4.47e-08	-2.17e-01	-0.1899
6548	SLC9A1	A001-C-014	Human	Colorectum	FAP	1.98e-02	-1.40e-01	0.0135
6548	SLC9A1	CRC-1-8810	Human	Colorectum	CRC	3.16e-03	-1.69e-01	0.6257
6548	SLC9A1	LZE7T	Human	Esophagus	ESCC	1.80e-03	1.43e-01	0.0667
6548	SLC9A1	LZE20T	Human	Esophagus	ESCC	2.44e-07	1.54e-01	0.0662
6548	SLC9A1	LZE24T	Human	Esophagus	ESCC	2.29e-10	2.39e-01	0.0596
6548	SLC9A1	P1T-E	Human	Esophagus	ESCC	2.69e-04	3.52e-01	0.0875

Page: 1 2 3 4 5

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Colorectum (GSE201348)		FAP: Familial adenomatous polyposis
		CRC: Colorectal cancer
Colorectum (HTA11)		AD: Adenomas
		SER: Sessile serrated lesions
		MSI-H: Microsatellite-high colorectal cancer
		MSS: Microsatellite stable colorectal cancer
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
GC		CAG: Chronic atrophic gastritis
		CAG with IM: Chronic atrophic gastritis with intestinal metaplasia
		CSG: Chronic superficial gastritis
		GC: Gastric cancer
		SIM: Severe intestinal metaplasia
		WIM: Wild intestinal metaplasia
Lung		AAH: Atypical adenomatous hyperplasia
		AIS: Adenocarcinoma in situ
		IAC: Invasive lung adenocarcinoma
		MIA: Minimally invasive adenocarcinoma
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:0007015	Colorectum	AD	actin filament organization	167/3918	442/18723	1.65e-16	7.94e-14	167
GO:0006839	Colorectum	AD	mitochondrial transport	102/3918	254/18723	1.87e-12	3.08e-10	102
GO:1902903	Colorectum	AD	regulation of supramolecular fiber organization	139/3918	383/18723	2.01e-12	3.19e-10	139
GO:0032970	Colorectum	AD	regulation of actin filament-based process	142/3918	397/18723	4.05e-12	5.90e-10	142
GO:0110053	Colorectum	AD	regulation of actin filament organization	108/3918	278/18723	5.02e-12	6.98e-10	108
GO:0032956	Colorectum	AD	regulation of actin cytoskeleton organization	127/3918	358/18723	1.03e-10	1.04e-08	127
GO:1902600	Colorectum	AD	proton transmembrane transport	66/3918	157/18723	1.59e-09	1.17e-07	66
GO:0034329	Colorectum	AD	cell junction assembly	136/3918	420/18723	2.02e-08	1.15e-06	136
GO:0010810	Colorectum	AD	regulation of cell-substrate adhesion	81/3918	221/18723	4.80e-08	2.55e-06	81
GO:0032868	Colorectum	AD	response to insulin	91/3918	264/18723	2.02e-07	8.48e-06	91
GO:0150115	Colorectum	AD	cell-substrate junction organization	44/3918	101/18723	2.38e-07	9.81e-06	44
GO:0007006	Colorectum	AD	mitochondrial membrane organization	48/3918	116/18723	4.53e-07	1.72e-05	48
GO:0031589	Colorectum	AD	cell-substrate adhesion	116/3918	363/18723	4.68e-07	1.76e-05	116
GO:0007163	Colorectum	AD	establishment or maintenance of cell polarity	77/3918	218/18723	5.72e-07	2.08e-05	77
GO:0007044	Colorectum	AD	cell-substrate junction assembly	41/3918	95/18723	8.20e-07	2.85e-05	41
GO:1901653	Colorectum	AD	cellular response to peptide	114/3918	359/18723	8.32e-07	2.88e-05	114
GO:0032869	Colorectum	AD	cellular response to insulin stimulus	72/3918	203/18723	1.10e-06	3.68e-05	72
GO:0070997	Colorectum	AD	neuron death	114/3918	361/18723	1.13e-06	3.72e-05	114
GO:0061572	Colorectum	AD	actin filament bundle organization	60/3918	161/18723	1.33e-06	4.23e-05	60
GO:0071375	Colorectum	AD	cellular response to peptide hormone stimulus	95/3918	290/18723	1.50e-06	4.66e-05	95

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Enriched KEGG pathways.

Pathway ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	qvalue	Count
hsa04919	Colorectum	AD	Thyroid hormone signaling pathway	51/2092	121/8465	1.71e-05	1.73e-04	1.10e-04	51
hsa05205	Colorectum	AD	Proteoglycans in cancer	70/2092	205/8465	1.37e-03	8.46e-03	5.39e-03	70
hsa04810	Colorectum	AD	Regulation of actin cytoskeleton	75/2092	229/8465	3.36e-03	1.76e-02	1.12e-02	75
hsa04971	Colorectum	AD	Gastric acid secretion	29/2092	76/8465	6.25e-03	2.68e-02	1.71e-02	29
hsa04260	Colorectum	AD	Cardiac muscle contraction	32/2092	87/8465	7.92e-03	3.13e-02	2.00e-02	32
hsa04972	Colorectum	AD	Pancreatic secretion	36/2092	102/8465	1.06e-02	3.98e-02	2.54e-02	36
hsa049191	Colorectum	AD	Thyroid hormone signaling pathway	51/2092	121/8465	1.71e-05	1.73e-04	1.10e-04	51
hsa052051	Colorectum	AD	Proteoglycans in cancer	70/2092	205/8465	1.37e-03	8.46e-03	5.39e-03	70
hsa048101	Colorectum	AD	Regulation of actin cytoskeleton	75/2092	229/8465	3.36e-03	1.76e-02	1.12e-02	75
hsa049711	Colorectum	AD	Gastric acid secretion	29/2092	76/8465	6.25e-03	2.68e-02	1.71e-02	29
hsa042601	Colorectum	AD	Cardiac muscle contraction	32/2092	87/8465	7.92e-03	3.13e-02	2.00e-02	32
hsa049721	Colorectum	AD	Pancreatic secretion	36/2092	102/8465	1.06e-02	3.98e-02	2.54e-02	36
hsa049192	Colorectum	SER	Thyroid hormone signaling pathway	40/1580	121/8465	1.02e-04	1.06e-03	7.67e-04	40
hsa042602	Colorectum	SER	Cardiac muscle contraction	31/1580	87/8465	1.30e-04	1.30e-03	9.47e-04	31
hsa049712	Colorectum	SER	Gastric acid secretion	27/1580	76/8465	3.65e-04	3.27e-03	2.38e-03	27
hsa052052	Colorectum	SER	Proteoglycans in cancer	58/1580	205/8465	4.37e-04	3.82e-03	2.77e-03	58
hsa048102	Colorectum	SER	Regulation of actin cytoskeleton	60/1580	229/8465	2.74e-03	2.02e-02	1.47e-02	60
hsa049722	Colorectum	SER	Pancreatic secretion	30/1580	102/8465	5.41e-03	3.28e-02	2.38e-02	30
hsa049193	Colorectum	SER	Thyroid hormone signaling pathway	40/1580	121/8465	1.02e-04	1.06e-03	7.67e-04	40
hsa042603	Colorectum	SER	Cardiac muscle contraction	31/1580	87/8465	1.30e-04	1.30e-03	9.47e-04	31

Page: 1 2 3 4 5

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

SLC9A1

SNV

Missense_Mutation

c.17N>A

p.Gly6Asp

p.G6D

P19634

protein_coding

deleterious_low_confidence(0)

possibly_damaging(0.672)

TCGA-BH-A0HF-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Hormone Therapy

arimidex

SLC9A1

SNV

Missense_Mutation

novel

c.1710G>T

p.Glu570Asp

p.E570D

P19634

protein_coding

deleterious(0.02)

benign(0.119)

TCGA-C8-A1HK-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unknown

SLC9A1

SNV

Missense_Mutation

c.2054N>A

p.Thr685Lys

p.T685K

P19634

protein_coding

deleterious(0.01)

benign(0.042)

TCGA-E2-A1IK-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Hormone Therapy

arimidex

SLC9A1

insertion

In_Frame_Ins

novel

c.984_985insTTTGGGAGG

p.Val328_Ile329insPheGlyArg

p.V328_I329insFGR

P19634

protein_coding

TCGA-AN-A0AL-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Unknown

SLC9A1

insertion

Frame_Shift_Ins

novel

c.983_984insGGCTCACGCCTGTAATCCCAGCA

p.Ile329AlafsTer37

p.I329Afs*37

P19634

protein_coding

TCGA-AN-A0AL-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Unknown

SLC9A1

deletion

Frame_Shift_Del

c.431delN

p.Gly144AlafsTer2

p.G144Afs*2

P19634

protein_coding

TCGA-BH-A0HA-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unknown

SLC9A1

SNV

Missense_Mutation

novel

c.134C>T

p.Thr45Ile

p.T45I

P19634

protein_coding

deleterious_low_confidence(0.03)

benign(0)

TCGA-2W-A8YY-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

cisplatin

SLC9A1

SNV

Missense_Mutation

rs556347900

c.2342N>T

p.Ala781Val

p.A781V

P19634

protein_coding

deleterious(0.03)

benign(0.03)

TCGA-BI-A0VS-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Unknown

SLC9A1

SNV

Missense_Mutation

novel

c.294N>A

p.His98Gln

p.H98Q

P19634

protein_coding

deleterious(0.01)

possibly_damaging(0.612)

TCGA-C5-A8YT-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

cisplatin

SLC9A1

SNV

Missense_Mutation

c.487N>T

p.Leu163Phe

p.L163F

P19634

protein_coding

deleterious(0.03)

benign(0.12)

TCGA-EX-A69M-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Unknown

Page: 1 2 3 4 5 6 7 8 9

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID	Symbol	Category	Interaction Types	Drug Claim Name	Drug Name	PMIDs
6548	SLC9A1	TRANSPORTER, DRUGGABLE GENOME, EXCHANGER, CELL SURFACE		CARIPORIDE	CARIPORIDE	17493937
6548	SLC9A1	TRANSPORTER, DRUGGABLE GENOME, EXCHANGER, CELL SURFACE		Zoniporide hydrochloride
6548	SLC9A1	TRANSPORTER, DRUGGABLE GENOME, EXCHANGER, CELL SURFACE		HOE-694	CHEMBL62231	17493937

Page: 1